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OBJECTIVES: Evaluate the use of probiotics as an additional therapy in the treatment of children and
adolescents with asthma in Belo Horizonte, MG-Brazil.
METHODS: A pilot longitudinal, experimental and nonrandomized study with 30 patients from six to 17 years
old from Belo Horizonte. In the baseline appointment, all patients received beclomethasone, and one group
also received a probiotic containing Lactobacillus reuteri (n=14). The patients were reassessed after at least 60
days with the Asthma Control Test, spirometry and self-report of the symptoms they experienced associated
with asthma.
RESULTS: A predominance of male patients (56.7%) and a mean age of 10.6 years were observed. The groups
using probiotics did not differ in terms of sex, age or atopy. In the longitudinal evaluation, an increase in the
Asthma Control Test scores and a reduction in the number of symptoms were observed in the probiotic group.
There was an increase in the peak expiratory flow among those who used probiotics.
CONCLUSIONS: This pilot study supports the hypothesis that the administration of probiotics as a supplementary
therapy for the treatment of children and adolescents with asthma improves the clinical condition of the
patients. Further studies are needed to confirm the efficacy of probiotics in asthma treatment.
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’ INTRODUCTION
Asthma involves inflammation of the airway that leads to a
variable obstruction of the intrapulmonary airflow, leading to
recurrent episodes of breathlessness, wheezing, chest tightness
and coughing (1,2). Asthma is the most common chronic
disease in childhood (3), and it is estimated that up to 14% of
children and 8.6% of adults worldwide have symptoms of this
pathology (4). There is a low mortality rate associated with
asthma (3); however, it imposes considerable financial and
social costs and is a prevalent cause of disability (5).
According to the guidelines of the Global Initiative for
Asthma (2), the primary goal of asthma treatment is to obtain
optimal control of the disease, with minimal or no day and
night symptoms, no limitations on physical activity, a mini-
mum need for medication for the relief of symptoms, normal
or nearly normal pulmonary function, and the absence of
exacerbations. These goals must be obtained with the use the
lowest possible amount of medication, especially corticoster-
oids, according to a phased plan that takes into consideration
the control of the disease, its severity and future risks (1,6).
The use of probiotics arises as a possible additional therapy.
Probiotics are defined as "live microorganisms that when
administered in adequate amounts, confer benefits to the
host’s health" (7,8). The use of these organisms could provide
benefits to the patient’s immune system, leading to better
control of the disease, with a reduction in symptoms and an
improvement in lung function in these patients. In addition,DOI: 10.6061/clinics/2019/e950
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other mechanisms of action of the probiotics include the
increase in the epithelial barrier, adhesion to the intestinal
mucosa, inhibition of the adhesion of pathogens, exclusion of
pathogenic microorganisms by competition and anti-micro-
organism substance production (7-9).
Several studies have investigated the possible benefits of
probiotics for the prevention and/or treatment of asthma.
A pilot study conducted by Stockert et al. investigated the
effects of probiotics in asthmatic children (10) and found an
improvement in lung function (peak of expiratory flow
[PEF]) but no impact on the patients’ quality of life and use
of asthma medications. Furthermore, Chen et al. (11) obser-
ved improvements in symptoms, lung function and immu-
nological parameters in children who received probiotics.
Liu et al. (12) suggested that probiotics could enhance the
therapeutic effect of allergen-specific immunotherapy in
patients with asthma. In studies performed in rats with
allergic inflammation of the airways receiving injections of
Lactobacillus reuteri, Forsythe et al. (13) and Karimi et al. (14)
observed a mitigation of inflammation and airway hyperre-
sponsiveness in the group of animals that received the pro-
biotic. However, there are some studies in which there was
no evidence of beneficial effects of probiotics on patients
with asthma or allergies (15-20). These include the study by
Giovannini et al. (15) in Italy with children with allergic
asthma and/or rhinitis from two to five years. The authors
found that the administration of probiotics did not promote
improvements among patients with asthma with regard to
time free from symptoms or the number of episodes of the
disease.
Rose et al. (16), examining the impact of Lactobacillus
rhamnosus GG ATCC 53103 in children aged 6 to 24 months
with wheezing for six months and a family history of atopic
diseases (in first-degree relatives), also found no association
between inhaled medication need and the number of days
free from symptoms among children who received or did not
receive the probiotics.
Given the current controversy about the use of probiotics
in children with asthma, the aim of this pilot study was to
evaluate the effect of including probiotics as a therapy sup-
plementary to treatment with the inhaled corticosteroid (ICS)
dipropionate beclomethasone among children and adoles-
cents with asthma in a secondary referral unit (SRU) of Belo
Horizonte, MG-Brazil. In particular, this study investigated
the effect of Lactobacillus reuteri because there are no pre-
vious Brazilian studies investigating its possible use in this
population.
’ METHODS
Study design
This was a longitudinal, quasi-experimental pilot study
with a control group involving children and adolescents with
asthma aged between 6 and 17 years old and treated in an SRU
in Belo Horizonte between January 2015 and December 2015.
Study participants
Children and adolescents who were newly diagnosed with
mild to moderate asthma (2) and who had not been pre-
viously prescribed an ICS or short-acting beta2-agonist
(SABA) were included. Patients with other respiratory
disorders, such as bronchiolitis obliterans, interstitial pneu-
monia, sickle-cell disease, cystic fibrosis, and sequelae due
to complicated pneumonia, tuberculosis or primary ciliary
dyskinesia, were excluded. In addition, smokers and patients
with cognitive impairment in the first attempt after initiation
of the study were excluded.
During the baseline appointment, all children received an
initial dose and a prescription for the conventional therapy,
beclomethasone (Clenils 250 mg/shot - Laboratory Chiesi,
Brazil), at a dose of 250 mg, twice daily (500 mg/day) and the
informed consent forms were signed. Aerolins (salbutamol
sulphate 120.5 mcg, norflurane S.p. Laboratory Gsk, Brazil),
at a dose of 100 mg, was prescribed for use in case of
exacerbations. One group received the probiotic ProVances
(Laboratory Aché, Brazil) composed of 108 colony-forming
units (CFU) of Lactobacillus reuteri DS 17938 at a dosage of
one capsule (108 CFU)/day (8), and the other group received
a placebo (no additional treatment for asthma). The alloca-
tion was performed in accordance with the final digit of the
patient record, with patients with odd numbers receiving the
probiotic.
Study outcomes
To evaluate the effects of the probiotic, the patients were
reassessed within a minimum period of 60 days after the
initiation of treatment. The outcomes of interest were asthma
control, pulmonary function and the frequency of the main
asthma symptoms.
At the two appointments, patients completed the asthma
control test (ACT) (21), a spirometry with bronchodilator test
and an assessment of the following symptoms: coughing,
wheezing, tiredness, chest pains, night-time symptoms (all
symptoms cited before occurring at night), limitations on
physical activities and any school absenteeism. A skin allergy
test was performed only at the baseline appointment to
identify atopic patients. A list of potential adverse effects of
probiotics was given to the patients and their caregivers,
with the instructions to monitor their occurrence during
treatment.
ACT
Nathan et al. (22) developed the ACT to monitor the
responsiveness to clinical changes. It has been validated with
internal consistency. The questionnaire has been validated
for use in Brazil (21) and is able to discriminate controlled
from uncontrolled asthma, with good reproducibility and
responsiveness of the questionnaire among Brazilian patients.
The ACT has five questions and assesses the frequency of
shortness of breath and general asthma symptoms, the use of
rescue medications, the effect of asthma on daily functioning,
and an overall self-assessment of asthma control in the last
four weeks. Scores range from 5 (poor control of asthma) to 25
(complete control of asthma), and high scores reflect greater
degrees of asthma control. Asthma is classified as controlled if
the score is greater than 19.
Spirometry
The spirometry test was performed using the VMI ATS
system (Clement Clarke, EC0120, United Kingdom) in
standing patients, with the mouthpiece of a disposable
spirometer positioned in the mouth and the nostrils closed
with a nose clip. The test was administered by an accredited
technician. The device was calibrated daily prior to testing.
The patients performed a maximum inspiration followed by
a maximum forced exhalation. This procedure was repeated
three times before and 15-20 minutes after inhalation of a
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fast-acting bronchodilator spray, Aerolins (salbutamol sul-
fate 120.5 mcg, norflurane S.p. Laboratory Gsk, Brazil).
Measurements were performed to determine the forced vital
capacity (FVC), forced expiratory volume in one second
(FEV1), PEF and Tiffeneau index (FEV1/FVC). The predicted
values were obtained from the equations provided by
Koopman et al. (23).
Evaluation of adverse effects
The caregivers were questioned about the occurrence of
the following symptoms that could indicate any adverse
reactions to probiotics. These included diarrhea, vomiting,
nausea, abdominal discomfort, burning sensation in the
stomach and/or a bad taste in their mouth not related to the
patients’ food.
Data analysis
This was a pilot study designed to be an exploratory
analysis and as a proof of concept study about the inclusion
of probiotics as a supplementary treatment for asthma. There
was no calculation of the necessary sample size. The findings
were intended be used to calculate the sample size for a
larger future study.
The categorical variables are presented as frequencies, and
the numerical variables are presented as the means± standard
deviation (sd), when normally distributed (assessed via
the Shapiro-Wilk test), or as the medians ± interquartile
ranges (IQRs), when nonnormally distributed. To evaluate
the associations among the categorical variables, Fisher ’s
exact test was used for independent samples, and the
McNemar chi-square test was used for the longitudinal
analysis. For the comparison of numerical variables between
two groups, Student’s t tests and Wilcoxon rank-sum tests
were used for independent samples and paired samples,
respectively. The analyses were performed with the free
program R version 3.3.2. We considered significant po0.05.
Ethical approval
This study was approved by the Research Ethics Commit-
tee of the University Hospital São José/University Medical
Sciences - MG under the number CAAE 36416714.4.0000.
5134.
’ RESULTS
In total, 37 patients met the inclusion criteria; four patients
were excluded because they were present at only one
appointment (one in the probiotic group), and three were
excluded because they had their second appointments
fewer than 60 days after the baseline appointment (one
in the probiotic group). The sample was composed of
30 children and adolescents, and 14 received the probiotic.
There was a predominance of males (56.7%), the mean age
was 10.6±2.5 years, and the mean body mass index (BMI)
was 18.8±3 kg/m2. The median time between the baseline
and second appointments was 63±7 days; 63.3% of the
patients had previously been hospitalized, 80% had pre-
viously sought emergency care, and 70% were classified as
atopic subjects according to the results of the allergy tests
conducted at the baseline. Among the patients using pro-
biotics, 50% were boys, the mean age was 11±2.5 years, the
mean BMI was 19.9±3.4 kg/m2, 42.9% had previously been
hospitalized, 64.3% had previously received emergency care,
and 71.4% were atopic. There were no significant differences
in patient characteristics between the control and interven-
tion groups (Table 1).
In the longitudinal evaluation, there was a significant
increase in ACT scores (difference mean ± sd 3.85±6.7,
p=0.049) (Figure 1) and a significant reduction in the number
of symptoms (difference mean ± sd -2.64±3.48, p=0.023)
among the patients who used probiotics. In addition, there
was a reduction in the number of patients who reported
wheezing (78.6% to 21.4%, p=0.046). There were no signifi-
cant changes in the control group (Table 2).
Regarding the parameters measured by prebronchodilator
spirometry, there was an increase in PEF among patients
who did not receive the probiotic (difference mean ± sd
12.47±12.33%, p=0.005) and those who did (difference
mean ± sd 17.89±17.54, p=0.005) (Table 3).
The occurrences of the signs of possible adverse effects
did not differ between patients who did or did not receive
the probiotic.
’ DISCUSSION
The groups were similar and comparable. There were no
significant differences in the characteristics of the groups of
Figure 1 - Asthma Control Test scores among patients using and
not using probiotics.
Table 1 - Clinical and sociodemographic characteristics of the
children and adolescents with asthma at the baseline.
Belo Horizonte, 2015.
Variables Controls
(n=16)
Probiotics
(n=14)
p-value
Male gender 10 (62.5%) 7 (50%) 0.713F
Follow-up time (days) 63±14 63.5±7 0.836W
Age (years) 10.2±2.5 11±2.5 0.383T
Body mass index (kg/m2) 17.8±2.2 19.9±3.4 0.059T
Prior hospitalization 13 (81.3%) 6 (42.9%) 0.057F
Prior emergency care 15 (93.8%) 9 (64.3%) 0.072F
Positive atopic allergy test 11 (68.8%) 10 (71.4%) 1.000F
F Fisher’s exact, T Student’s t and W the Wilcoxon Mann-Whitney tests for
independent samples.
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patients who did or did not receive L. reuteri. In the group
that received the supplement, an increase in ACT scores and
a decrease in the number of symptoms, in particular the
occurrence of wheezing, were seen, while no significant
changes were observed in the control group. The spirometry
results were the same in the two groups (longitudinal
increase in the pre- bronchodilator PEF), which implies
that probiotics had no impact on patients’ spirometry tests.
The possible adverse effects evaluated were not associated
with the use of the supplement.
The longitudinal increase in prebronchodilator PEF indi-
cates a possible improvement in relation to the obstruction of
the lower airways by decreasing the bronchial hyperrespon-
siveness in all patients. These results may have been
influenced by the standard treatment (beclomethasone in
patients who were not previous users of either ICS or SABA),
the guidelines regarding the allergic markers and climatic
changes between the evaluations. The increase in PEF in
the sample, for example, was expected given the applica-
tion of regular ICS treatment for two months (2). Another
possible explanation would be a better performance of
patients on the second test due to the training they received
when they performed it previously. This is notable for PEF,
as it is a functional parameter that is effort dependent (24).
FEV1 is the most important follow-up parameter in patients
with asthma because its decrease increases the risk of
exacerbations, regardless of the presentation of relevant
symptoms (25).
The findings of this pilot study suggest that the use of
probiotics may promote an attenuation of clinical symptoms
because four of the five items evaluated by the ACT
are related to symptoms. However, this needs to be
evaluated further before any definitive statements can
be made due to the small sample size. These findings are
similar to those of Chen et al. (11), who showed a decrease
in asthma/allergic rhinitis symptoms and improvements
in FEV1, FVC and FEV1/FVC measured by spirometry and
PEF measured daily among patients who received probiotics.
The authors also reported a significant reduction in the
levels of immunological parameters measured in peripheral
blood mononuclear cells (TNF-a, IFN-g, IL-12 and IL-13).
However, we did not observe an improvement in lung
function in the probiotic group in our study. This difference
could be due to variations in the method used to measure
lung function.
Table 2 - Symptom history of the children and adolescents with asthma stratified according to their use of probiotics. Belo Horizonte,
2015.
Variables Measures Controls (n=16) Probiotics (n=14) p-value
Number of symptoms Baseline 2±5.5 4±3 0.054W
2nd consultation 1±2.5 1±3 0.669W
p-value 0.251Wp 0.023Wp
Cough Baseline 7 (43.8%) 13 (92.9%) 0.007F
2nd consultation 6 (37.5%) 7 (50%) 0.713F
p-value 1.000Mc -
Wheezing Baseline 5 (31.2%) 11 (78.6%) 0.014F
2nd consultation 1 (6.2%) 3 (21.4%) 0.316F
p-value 0.371Mc 0.046Mc
Tiredness Baseline 5 (31.2%) 10 (71.4%) 0.066F
2nd consultation 5 (31.2%) 4 (28.6%) 1.000F
p-value 1.000Mc 0.077Mc
Chest pain Baseline 4 (25%) 5 (35.7%) 0.694F
2nd consultation - 2 (14.3%) 0.209F
p-value - 0.371Mc
Nighttime symptoms Baseline 10 (62.5%) 10 (71.4%) 0.709F
2nd consultation 4 (25%) 5 (35.7%) 0.694F
p-value 0.131Mc 0.131Mc
Limitations on physical activities Baseline 4 (25%) 5 (35.7%) 0.694F
2nd consultation 2 (12.5%) 4 (28.6%) 0.378F
p-value 1.000Mc 1.000Mc
Absent from school Baseline 7 (43.8%) 7 (50%) 1.000F
2nd consultation 4 (25%) 3 (21.4%) 1.000F
p-value 0.617Mc 0.221Mc
F Fisher’s exact, Mc the McNemar Chi-square, Wp and the Wilcoxon tests for paired samples and W the Wilcoxon Mann-Whitney test for independent
samples.
Table 3 - Pre-salbutamol spirometry parameters, as percentages
of the predicted values, in the children and adolescents with
asthma stratified according to their use of probiotics.
Belo Horizonte, 2015.
Variables Controls (n=16) Probiotics (n=14) p-value
FEV1 (L)
Baseline 77.6±16.9 79.4±14 0.667W
2nd consultation 81.5±8.4 85.5±8.1 0.242W
p-value 0.301Wp 0.147Wp
FVC (L)
Baseline 54.1±15.3 61.5±26.8 0.381T
2nd consultation 57.4±20.5 68.1±25.7 0.254T
p-value 0.947Tp 0.396Tp
FEV1/FVC (%)
Baseline 104±15.1 97±21.6 0.910W
2nd consultation 106.8±10.3 106.9±14.1 0.920W
p-value 0.476Wp 0.306Wp
PEF (L/min)
Baseline 75.5±19.5 74.9±17.3 0.928T
2nd consultation 85.7±20.2 86.8±16.5 0.871T
p-value 0.005Tp 0.005Tp
T Student’s t and W the Wilcoxon Mann-Whitney tests for independent
samples and Tp Student’s t and Wp the Wilcoxon tests for paired samples.
FEV1 = forced expiratory volume in one second; FVC = forced vital
capacity, PEF = peak expiratory flow
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In addition, Stockert et al. (10) found a reduction in the
variation in PEF in patients who used a probiotic; however,
no differences were identified in the assessment of FEV1,
quality of life and use of extra medications. The findings
from Stockert et al. (10) resemble those of the present study
with respect to improvements in lung function, evaluated in
this case by the daily variation in PEF measured with a
portable measuring instrument. The differences observed in
the results between the two studies could potentially be
explained by the use of different strains of probiotics, which
might provide different benefits to the host (8).
Prescott and Bjorksten (26) reported that the effects of
probiotics on allergic diseases can be influenced by factors
such as genetic differences in microbial responses, microbial
composition, individual microbiota, diet, allergic predisposi-
tion and the use of antibiotics, which could also account for
the different results observed. However, in our study, we did
not find an association between the probiotic effect and the
allergic profile.
With regard to the limitations of this study, there were
quasi-experimental characteristics (nonrandomization and
lack of blinding of participants and researchers). Koopman’s
equations that were used to derive the predicted values of
spirometry parameters were developed based on a sample
that included those in the age ranges of children and adoles-
cents. There are no national equations recently published
derived from a sample of Brazilian children and adolescents
up to the time of the initiation of this study. The ACT was
developed for adolescents of at least 12 years old. The
application of the ACT to a sample of patients younger than
12 years old in this study is mitigated because children
younger than 12 years old were helped by their caregivers
when completing the questionnaire.
The results of this pilot study suggest a trend towards
improvement of the clinical profile of asthmatic patients who
received L. reuteri as a supplementary therapy.
This is one of the first investigations on the efficacy of
probiotics performed with Brazilian children and adolescents
with asthma. However, given conflicting results in the litera-
ture, the known variability in the effects of probiotics for each
strain, and the current lack of knowledge of the mechanism
underlying the potential benefits of probiotics in patients with
asthma, we believe that more studies are necessary, especially
randomized controlled clinical trials and prospective cohort
studies, to gather more evidence and knowledge of the
possible potential benefits of probiotics in asthmatic patients
before their routine use in children can be advocated.
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